Hosted on MSN29d
Sonnet BioTherapeutics appoints new chief business officeras reflected in a current ratio of 0.66. Sonnet BioTherapeutics does not undertake any obligation to update these forward-looking statements in the event of new information or future developments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results